Efgartigimod, ARGX-113
ARGX-113-1902
Phase 2 small_molecule active
Quick answer
Efgartigimod, ARGX-113 for Chronic Inflammatory Demyelinating Polyneuropathy is a Phase 2 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Argenx
- Indication
- Chronic Inflammatory Demyelinating Polyneuropathy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active